Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2021

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA) will report its fiscal Q1 results for the period ending December 31, 2021, on February 8, 2022, post-market. The company will hold a conference call at 4:30 p.m. ET to discuss these results and its R&D pipeline. Enanta focuses on developing small molecule drugs targeting viral infections and liver diseases. Its R&D is supported by royalties from its collaboration with AbbVie on hepatitis C products, notably Glecaprevir, which is marketed as MAVYRET® and MAVIRET®.

Positive

• Enanta is advancing clinical candidates targeting RSV, SARS-CoV-2, and HBV, indicating continued innovation.
• Continued funding for R&D from royalties generated by hepatitis C product sales suggests a sustainable revenue stream.

Negative

• None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2021 after the U.S. market closes on February 8, 2022. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Conference Call and Webcast Information

To participate in the live conference call, please dial 844-467-7101 in the U.S. or 270-215-9353 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on February 8, 2022, through 11:59 p.m. ET on February 15, 2022 by dialing 855-859-2056 from the U.S. or 404-537-3406 for international callers. The passcode for both the live call and the replay is 3458965. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220201005255/en/

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta Pharmaceuticals report its earnings for Q1 2022?

Enanta Pharmaceuticals will report its fiscal Q1 earnings on February 8, 2022.

What time is the Enanta Pharmaceuticals conference call on February 8, 2022?

The conference call is scheduled for 4:30 p.m. ET on February 8, 2022.

What are the main focuses of Enanta Pharmaceuticals' research and development?

Enanta Pharmaceuticals is focused on developing drugs for viral infections including RSV, SARS-CoV-2, and hepatitis B.

How does Enanta Pharmaceuticals fund its research and development?

Enanta funds its R&D primarily through royalties from hepatitis C virus products developed with AbbVie.

What is the significance of Glecaprevir in Enanta's financials?

Glecaprevir generates royalties for Enanta, supporting its research and development activities.